Publication by Renz et al.: Inhibition of FGF and TGF-β Pathways in hESCs Identify STOX2 as a Novel SMAD2/4 Cofactor.

Renz and colleagues examined how two pathways (the transforming growth factor- (TGF-beta) and the fibroblast growth factor (FGF)) cooperate in the maintenance and cell fate specification of human embryonic stem cells. They discovered STOX2 as a new primary target of the TGF-beta signaling pathway, suggesting that STOX2 acts as a novel TGF-beta signaling co-factor. Their work will contribute understanding how signaling by the TGF-beta is mediated.